"Valuation metrics in some sectors do appear substantially stretched—particularly those for smaller firms in the social media and biotechnology industries, despite a notable downturn in equity prices for such firms early in the year," said remarks in the full policy report accompanying Yellen's testimony.
So did the entire biotech sector hire cfo's today ...come on, tell your brain cells to hold hands.
You are a real dimwit you know that...look at the biotech sector dude...MNKD MannKind Corp. -0.09 -0.90% 9.88 242.16M 3.8 11.48 - - - - 10.02 9.97 0.046 -
GILD Gilead Sciences Inc. -0.34 -0.38% 89.51 1.53B 55.96 90.74 - - - - 83.0456 89.85 8.736 -
CLDX Celldex Therapeutics, Inc. -0.53 -3.68% 13.87 89.11M 10.76 38.84 - - - - 15.91 14.40 3.27 -
MYGN Myriad Genetics Inc. -1.46 -3.61% 38.95 74.50M 20.02 42.5 - - - - 36.29 40.41 9.69 -
ACAD ACADIA Pharmaceuticals Inc. -0.59 -2.67% 21.50 73.29M 15.64 32 - - - - 22.35 22.09 3.7 -
IBB iShares Nasdaq Biotechnology -3.85 -1.49% 254.25 0.00 187.05 275.4 - - - - 251.11 258.10 0 -
SLV iShares Silver Trust -0.18 -0.92% 19.92 - 17.91 23.84 - - - - 19.33 20.10 - -
CPHD Cepheid -1.19 -2.38% 48.76 68.67M 30.95 55.89 - - - - 46.77 49.95 5.07 -
VTI Vanguard Total Stock Market ETF -0.24 -0.23% 101.99 - 84.6 103 - - - - 101.18 102.23 - 1.08
QQQ PowerShares QQQ -0.32 -0.33% 95.52 0.00 74.2 96.13 - - - - 93.11 95.84 0 -
GLD SPDR Gold Shares -0.91 -0.72% 124.81 - 114.46 137.55 - - - - 124.26 125.72 - -
Believe me even if the Biotech was 50% lower they would still say it is over valued. They really want dirt cheap drug costs.
When I worked for one of the biggest HMO's in the west coast who had their own pharmacy, it was hammered home at EVERY MEETING...the biggest expense...was not the hospital cost....not malpractice insurance...but the cost of drugs, especially new brand name drugs. They bombarded us with graphs and charts about generics vs brand name meds over and over again. They sent out individual stat sheets comparing your own drug prescriptions use compared to all your other doctors so you could see if you were ordering more brand name drugs than the average doctor. If you you were an outlier you had a month or so to get back in line...if you didn't, you had a sit down with the Chief of your Dept. Ouch! If that didn't get your attention then how about a 10% cut in pay if you were on contrat or "full time " doc. Of course if you were just a per diem...they would just not give you hours, basically they fired you. So get the picture. So what does this have to do with biotechs and the fed....MEDICARE. Do you understand what is happening right now....Millions upon millions of baby boomers are getting Medicare ...we paid for it via SS and now at 65 its an entitlement, although the government is still sticking it to us with the extra fees if you "make too much " ie Obama Care. It is still eating up a humongous amount of government funds and the one thing they can't get a handle on is drug costs.
This guy is a great fit...ton's of experience in Biotech. CPA is a an excellent degree for a CFO, and a JD from Vanderbilt to boot. He will work out just fine.
Mr. Davis brings over 20 years of executive-level experience in the pharmaceutical industry. He most recently served as Executive Vice President and Chief Operating Officer at Heron Therapeutics, Inc., which he joined in 2013. He led core business and finance functions there and was instrumental in developing and implementing a new corporate strategy with a multi-program portfolio. Previously, Mr. Davis served as Executive Vice President and Chief Operating Officer at Ardea Biosciences, Inc. from 2010 to 2013, where he oversaw business functions, including finance, commercial planning, and corporate development, and played a critical role in building and growing the company. Prior to joining Ardea, Mr. Davis served in numerous executive roles at Neurogen Corporation from 1994 to 2010, including Chief Financial Officer, Chief Operating Officer, and Chief Executive Officer, completing multiple collaborations and product acquisitions with global pharmaceutical companies. Mr. Davis currently serves on the Board of Directors of Heron Therapeutics and Synageva BioPharma Corp.
Earlier in his career, Mr. Davis practiced as a Certified Public Accountant with a major accounting firm and as a corporate and securities attorney with a Wall Street law firm. Mr. Davis received his Bachelor of Science degree in Accounting from Southern Nazarene University and a J.D. from Vanderbilt University.
I agree the $22..50 seemed really weak . I was very surprised it cracked so easily-Perhaps because the stock opened so weak. $hit happens I guess. But in general, the numbers are ...more like a guide with each number giving its relative strength. So chill and stop being such a numb skull and shut your pie hole, use it or ignore it, your choice.
Your relative has severe PDP and is an in-patient in a costly SNF- Then PIMA gets released and it stabilizes your relative enough to be discharged home from the SNF. Wow how cool is that.
The European Union has about 1.6 Million Parkinson's Disease patients. So 640,000 will need treatment for PDP at some point.
Many Biotech stocks go down after FDA approval, keep that in mind. But IF MNKD can get a Partner this stock will really fly. So just use money you can lose. If you can not afford to lose it, consider a mutual fund, eg, VTI ( total stock market) or IBB( biotech MF). You will need to leave it alone for a while to see the money grow. Good luck...and don't listen to anyone one on a stock message board...including me ;)
Well I could not find the cost of care in a nursing home for a PDP patient so I will just use the Alzheimer's cost which is probably close.
" According to the MetLife Mature Market Study, 68% of assisted living communities surveyed nationwide provide dementia and Alzheimer’s care for their residents. The study also found that the national average for Alzheimer’s care costs at an assisted living community is $4,762 per month or $57,144 annually."
I don't know if this just covers the stay and not meds or other special therapy etc.
So PIMA can keep patients out of a SNF( Skilled Nursing Facility also call a "sniff " ) . Actually the Range I noted was $4+-7,000/month for Alzheimer's care in a SNF. So if PIMA cost say $10 /day = x 30 d = $300/mo that is still a great savings. You can calculate the cost per year if you knew exactly how many patients were treated. eg, 1 million PD patients in the USA alone...40% or 400,000 will get PDP at some point, if you consider say 100,000 pt's need treatment now....100K x $300/mon x 12= $360 Million per year in the USA only. So the real incentive is to keep PDP pt's out of the SNF. $300 per month is way better than $4-7,000 per month. The insurance companies will have tremendous pressure to cover the cost of PIMA since it will be the only drug indicated for PDP Even if they use protocols they will still be liable if the patients get the risky side effects to the of say Clozapine -
"Main side effects
Agranulocytosis (1%), seizures, myocarditis, gastrointestinal hypomotility, weight gain, diabetes mellitus or hyperglycemia, hypercholesterolemia, orthostatic hypotension, sedation, sialorrhea. Clozapine bears a “black box” warning of potential for increased mortality risk in elderly dementia patients on conventional or atypical antipsychotics. (Most deaths are due to cardiovascular or infectious events it remains unclear if the deaths are due to antipsychotics or to patient characteristics or the patient population.)"
I posted this question and got not one answer. So some here feels MRK could pay $30/share or more for a buy out of MNKD, this amounts to approx. 11 BILLION ( PERHAPS CASH & STOCK)... A 300% premium ...So how much can MRK get in return per year? Please explain how you arrived at your number. I read something last week that Afrezza might have up to $600,000,000 per year sales....So if you were MRK CEO you would think that is a good deal?